Targeted therapeutics using small-molecule allosteric modulators of Trk receptors that in a biased manner activate important intracellular pathways could be key in future treatment of AD and other diseases characterized by disturbed neurotrophin signaling. Here, BDNF is linked to Alzheimer disease.